Introducing Angoss Version 9.6 Software Suite Release

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Introducing Angoss Version 9.6 Software Suite Release

TORONTO, April 20, 2016 (GLOBE NEWSWIRE) -- Angoss Software Corporation (Angoss) announces the release of version 9.6 Platform, which includes enhancements to current KnowledgeSEEKER™ , KnowledgeSTUDIO™ , KnowledgeREADER™ and InsightOPTIMIZER™ products.  Version 9.6 feature additions will considerably augment the current Angoss Data Science Platform offering, and continue to improve user experience and business performance.

With the rising trend in the adoption of credit scoring technology, Angoss further enhances its data preparation, advanced modeling, model evaluation and documentation automation to supply analysts with a complete toolset for end-to-end superior scorecard development functionality. KnowledgeSTUDIO software will now incorporate Partial Least Squares Regression, Constrained Regression, Regularization and Scorecard Editor which will provide users with the means to increase efficiencies when dealing with a large number of variables within a dataset, satisfy compliance requirements, solve complex business problems, and perform manual changes in score points and base score for ultimate scorecard accuracy.  The enrichment of Angoss’ scorecard functionality will provide lenders with one of the best scorecard methods to making accurate, reliable, and fast credit risk decisions with the added flexibility to incorporate their own business understanding via manual modification for more business tailored lending approaches.

In the new 9.6 Platform, Angoss boosts its prescriptive analytics product, InsightOPTIMIZER, by incorporating dataset and record level optimization to accommodate the evident proliferation of optimization use cases and industry applications.  This functionality addition further optimizes the business strategy development process by providing users more control at the problem set-up stage while maintaining its ease-of-use with helpful wizards that progress new users through the optimization phases. Designed to help users solve complex business problem with ease, InsightOPTIMIZER, determines the next strategic business move while minimizing losses and maximizing results.

As part of Tableau phase two integration, Angoss has drastically enhanced the users’ visualization experience with pre-built templates for Logistic Regression, Cluster Analysis and Optimization scenario comparison.  This development will contribute to measurable time savings, improve collaboration amongst technical and business users, and improve model visualization output.

“Our aim is to consistently improve the user experience through our business centric product enhancements,” said Rick Makos, President and Chief Executive Officer at Angoss. “The advancements we have made to our software functionality truly enable us to offer customer solutions that contribute to significant efficiency gains, expand optimization possibilities, and generate faster results via customizable methods.”

Features and improved capabilities in 9.6 Platform include:

KnowledgeSEEKER ™ and KnowledgeSTUDIO ™

  • Data Preparation
    • Outlier Detector
    • Identification of special missing values  
    • Weight of Evidence (WOE) transformation process improvements
    • Transforming multiple variables at a time
    • Variable Selection Automation
    • Schema node
  • Decision Tree and Strategy Tree Enhancements
    • Global defaults for Tree Attribute Editor options 
    • Code generation for tagged nodes, current node and sub-branches
    • Treatments for non-terminal nodes in Strategy Trees
    • Paste Splits to multiple nodes at once   
  • Modeling
    • Partial Least Squares Regression (PLS Regression)
    • Constrained logistic regression
    • Regularization
    • Scorecard editor
    • Survival Analysis
    • Model Selector
  • Model Evaluation
    • Cross Validation
    • Variable Importance
    • Model Analyzer charts in Scorecard Editor
  • Automation of Process Documentation and Scripting
    • Automatic self-documentation of workflows
    • Automatic documentation of modeling nodes
    • Automatic generation of scripts for workflows in Angoss query language
    • Automatic generation of model training and scoring scripts in Angoss query language
  • Integration with business intelligence & visualization software
    • Integration with Qlik software
    • Integration with Tableau (enhancements of existing feature)
      • Pre-built templates for Logistic Regression and Cluster Analysis 
      • Dashboard template for comparing optimization scenarios
  • Workflow Usability Enhancements
    • Undo node deletion in workflows

KnowledgeREADER™

  • Advanced options for Text Analysis now include Tagging Threshold

InsightOPTIMIZER™

  • General Dataset Level Optimization
  • General Record Level Optimization

About Angoss Software Corporation

Angoss is a global leader in delivering predictive analytics to businesses looking to improve performance across risk, marketing and sales. With a suite of big data analytics software solutions and consulting services, Angoss delivers powerful approaches that provide you with a competitive advantage by turning your information into actionable business decisions.

Many of the world’s leading organizations in financial services, insurance, retail and high tech rely on Angoss to grow revenue, increase sales productivity and improve marketing effectiveness while reducing risk and cost. Headquartered in Toronto, Canada, with offices in the United States, United Kingdom and Singapore, Angoss serves customers in over 30 countries worldwide. For more information, visit www.angoss.com . 

Follow Angoss on Twitter for continuous company updates: @Angoss

Media Contact: Christina Ioannou, cioannou@angoss.com, 416 593 1122 x 2448

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading